Evinacumab for Homozygous Familial Hypercholesterolemia
University of the Witwatersrand · Cardiovascular Institute of the South · +5 more institutions
Abstract
) are associated with hypolipidemia and protection against atherosclerotic cardiovascular disease. Evinacumab, a monoclonal antibody against ANGPTL3, has shown potential benefit in patients with homozygous familial hypercholesterolemia.
In this double-blind, placebo-controlled, phase 3 trial, we randomly assigned in a 2:1 ratio 65 patients with homozygous familial hypercholesterolemia who were receiving stable lipid-lowering therapy to receive an intravenous infusion of evinacumab (at a dose of 15 mg per kilogram of body weight) every 4 weeks or placebo. The primary outcome was the percent change from baseline in the LDL cholesterol level at week 24.
Citation impact
- FWCI
- 63.10
- Percentile
- 100%
- References
- 24
Authors
16- FJFrederick J. RaalCorresponding
University of the Witwatersrand, Cardiovascular Institute of the South
- RSRobert S. Rosenson
Cardiovascular Institute of the South, Icahn School of Medicine at Mount Sinai
- LFLaurens F. Reeskamp
Cardiovascular Institute of the South, University of Amsterdam
- GKG. Kees Hovingh
Cardiovascular Institute of the South, University of Amsterdam
- JJJohn J.P. Kastelein
Cardiovascular Institute of the South, University of Amsterdam
Topics & keywords
- Familial hypercholesterolemia
- Internal medicine
- Null allele
- Null (SQL)
- Endocrinology
- LDL receptor
- Medicine
- PCSK9
- Good health and well-being